- Home
- AMSC vs MLYS Comparison
AMSC vs MLYS Comparison
Compare AMSC & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMSC
- MLYS
- Stock Information
- Founded
- AMSC 1987
- MLYS 2019
- Country
- AMSC United States
- MLYS United States
- Employees
- AMSC N/A
- MLYS N/A
- Industry
- AMSC Metal Fabrications
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- AMSC Consumer Discretionary
- MLYS Health Care
- Exchange
- AMSC Nasdaq
- MLYS Nasdaq
- Market Cap
- AMSC 1.1B
- MLYS 1.0B
- IPO Year
- AMSC 1991
- MLYS 2023
- Fundamental
- Price
- AMSC $53.75
- MLYS $13.67
- Analyst Decision
- AMSC Strong Buy
- MLYS Strong Buy
- Analyst Count
- AMSC 3
- MLYS 4
- Target Price
- AMSC $33.67
- MLYS $27.00
- AVG Volume (30 Days)
- AMSC 1.2M
- MLYS 667.8K
- Earning Date
- AMSC 07-30-2025
- MLYS 08-12-2025
- Dividend Yield
- AMSC N/A
- MLYS N/A
- EPS Growth
- AMSC N/A
- MLYS N/A
- EPS
- AMSC 0.39
- MLYS N/A
- Revenue
- AMSC $254,886,000.00
- MLYS N/A
- Revenue This Year
- AMSC $20.26
- MLYS N/A
- Revenue Next Year
- AMSC $12.73
- MLYS N/A
- P/E Ratio
- AMSC $136.18
- MLYS N/A
- Revenue Growth
- AMSC 63.73
- MLYS N/A
- 52 Week Low
- AMSC $13.98
- MLYS $8.24
- 52 Week High
- AMSC $57.86
- MLYS $18.38
- Technical
- Relative Strength Index (RSI)
- AMSC 77.22
- MLYS 45.18
- Support Level
- AMSC $43.24
- MLYS $13.41
- Resistance Level
- AMSC $57.86
- MLYS $15.15
- Average True Range (ATR)
- AMSC 2.55
- MLYS 0.73
- MACD
- AMSC 0.88
- MLYS 0.01
- Stochastic Oscillator
- AMSC 78.44
- MLYS 25.36
About AMSC American Superconductor Corporation
American Superconductor Corp generates the ideas, technologies, and solutions that meet the world's demand for smarter, cleaner, and energy. Through its Windtec Solutions, the company enables manufacturers to launch wind turbines quickly, effectively, and profitably. Through its Gridtec Solutions, the company provides engineering planning services and grid systems that optimize network reliability, efficiency, and performance. The company's segment includes Grid and Wind. It generates maximum revenue from the Grid segment.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.